Fig. 4

Comparative analysis of RD07 cell dynamics and therapeutic efficacy in PR versus PD patients pre- and postinfusion. a CT scans reveal a reduction in the tumor lesion of Patient 2 (PR patient) following RD07 infusion. b The expression levels of tumor markers in Patient 2 decreased after treatment. c UMAP feature representation of 11,853 CAR-T cells combined from two patients, identifying 14 distinct clusters of T cells on the basis of conventional markers. Color-coded by clusters and cell subsets as indicated. d Bar plots illustrating the relative abundance of each T-cell cluster in the products and engrafted CAR-T cells of patients with a PR or PD. Prod, product. e Expression levels of cytotoxicity-related genes in CAR-T cell products and engrafted CAR-T cells from patients with PR or PD. f Key pathways associated with each T-cell cluster from PR and PD patients revealed by GO enrichment analysis. g GSVA enrichment analysis highlighting differences in functional pathways between PR patients and PD patients. h The number of cells associated with different TCR clonotypes. i Pie chart displaying the percentages of different TCR clonotypes across different T-cell clusters. Statistical analysis was performed via unpaired two-tailed Wilcoxon–Mann–Whitney U tests. ****P < 0.0001